Conditional survival of malignant melanoma in The Netherlands: 1994–2008

Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2014-02, Vol.50 (3), p.602-610
Hauptverfasser: van der Leest, Robert J.T, van Steenbergen, Liza N, Hollestein, Loes M, de Vries, Esther, Nijsten, Tamar, van Akkooi, Alexander C.J, Janssen-Heijnen, Maryska L.G, Coebergh, Jan-Willem W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 610
container_issue 3
container_start_page 602
container_title European journal of cancer (1990)
container_volume 50
creator van der Leest, Robert J.T
van Steenbergen, Liza N
Hollestein, Loes M
de Vries, Esther
Nijsten, Tamar
van Akkooi, Alexander C.J
Janssen-Heijnen, Maryska L.G
Coebergh, Jan-Willem W
description Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with >4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.
doi_str_mv 10.1016/j.ejca.2013.10.019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492716009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S095980491300957X</els_id><sourcerecordid>1492716009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</originalsourceid><addsrcrecordid>eNp9kc1u1DAQgK0K1C6lL9ADygWJS5ax4yQ2QpWqFb-q4ECRuFmuPaEOid3ayUq98Q68YZ8ER7uA1AMnj0bfjGe-IeSUwpoCbV72a-yNXjOgVU6sgcoDsqKilSWImj0iK5C1LAVweUSepNQDQCs4HJIjxlnDalGvyMdN8NZNLng9FGmOW7fNQeiKUQ_uu9d-KkYctA-jLpwvLq-x-ITTNcacs-lVQaXk9z9_MQDxlDzu9JDwZP8ek69v31xu3pcXn9992JxflIZzOpUGhGm5ZdowKpgGFNUVQsepqayRWnLa4RJoJhjUkumG2bYBZjnVCE1dHZMXu743MdzOmCY1umRwyBNhmJOiXLKWNgAyo2yHmhhSitipm-hGHe8UBbU4VL1aHKrF4ZLLDnPRs33_-WpE-7fkj7QMPN8DOhk9dFF749I_TuQJsvTMvd5xmG1sHUaVjENv0LqIZlI2uP_Pcfag3AzOu_zjD7zD1Ic55qPlfVViCtSX5drLsWmVV6_bb9VvT22jKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492716009</pqid></control><display><type>article</type><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</creator><creatorcontrib>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</creatorcontrib><description>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with &gt;4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2013.10.019</identifier><identifier>PMID: 24262585</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Conditional survival ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Medical sciences ; Melanoma ; Melanoma - mortality ; Melanoma - pathology ; Melanoma, Cutaneous Malignant ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Netherlands - epidemiology ; Pharmacology. Drug treatments ; Prognosis ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Survival Analysis ; Tumors ; Young Adult</subject><ispartof>European journal of cancer (1990), 2014-02, Vol.50 (3), p.602-610</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</citedby><cites>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S095980491300957X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28149049$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24262585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Leest, Robert J.T</creatorcontrib><creatorcontrib>van Steenbergen, Liza N</creatorcontrib><creatorcontrib>Hollestein, Loes M</creatorcontrib><creatorcontrib>de Vries, Esther</creatorcontrib><creatorcontrib>Nijsten, Tamar</creatorcontrib><creatorcontrib>van Akkooi, Alexander C.J</creatorcontrib><creatorcontrib>Janssen-Heijnen, Maryska L.G</creatorcontrib><creatorcontrib>Coebergh, Jan-Willem W</creatorcontrib><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with &gt;4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Conditional survival</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - mortality</subject><subject>Melanoma - pathology</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Netherlands - epidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAQgK0K1C6lL9ADygWJS5ax4yQ2QpWqFb-q4ECRuFmuPaEOid3ayUq98Q68YZ8ER7uA1AMnj0bfjGe-IeSUwpoCbV72a-yNXjOgVU6sgcoDsqKilSWImj0iK5C1LAVweUSepNQDQCs4HJIjxlnDalGvyMdN8NZNLng9FGmOW7fNQeiKUQ_uu9d-KkYctA-jLpwvLq-x-ITTNcacs-lVQaXk9z9_MQDxlDzu9JDwZP8ek69v31xu3pcXn9992JxflIZzOpUGhGm5ZdowKpgGFNUVQsepqayRWnLa4RJoJhjUkumG2bYBZjnVCE1dHZMXu743MdzOmCY1umRwyBNhmJOiXLKWNgAyo2yHmhhSitipm-hGHe8UBbU4VL1aHKrF4ZLLDnPRs33_-WpE-7fkj7QMPN8DOhk9dFF749I_TuQJsvTMvd5xmG1sHUaVjENv0LqIZlI2uP_Pcfag3AzOu_zjD7zD1Ic55qPlfVViCtSX5drLsWmVV6_bb9VvT22jKA</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>van der Leest, Robert J.T</creator><creator>van Steenbergen, Liza N</creator><creator>Hollestein, Loes M</creator><creator>de Vries, Esther</creator><creator>Nijsten, Tamar</creator><creator>van Akkooi, Alexander C.J</creator><creator>Janssen-Heijnen, Maryska L.G</creator><creator>Coebergh, Jan-Willem W</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140201</creationdate><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><author>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Conditional survival</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - mortality</topic><topic>Melanoma - pathology</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Netherlands - epidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Leest, Robert J.T</creatorcontrib><creatorcontrib>van Steenbergen, Liza N</creatorcontrib><creatorcontrib>Hollestein, Loes M</creatorcontrib><creatorcontrib>de Vries, Esther</creatorcontrib><creatorcontrib>Nijsten, Tamar</creatorcontrib><creatorcontrib>van Akkooi, Alexander C.J</creatorcontrib><creatorcontrib>Janssen-Heijnen, Maryska L.G</creatorcontrib><creatorcontrib>Coebergh, Jan-Willem W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Leest, Robert J.T</au><au>van Steenbergen, Liza N</au><au>Hollestein, Loes M</au><au>de Vries, Esther</au><au>Nijsten, Tamar</au><au>van Akkooi, Alexander C.J</au><au>Janssen-Heijnen, Maryska L.G</au><au>Coebergh, Jan-Willem W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>50</volume><issue>3</issue><spage>602</spage><epage>610</epage><pages>602-610</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with &gt;4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24262585</pmid><doi>10.1016/j.ejca.2013.10.019</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0959-8049
ispartof European journal of cancer (1990), 2014-02, Vol.50 (3), p.602-610
issn 0959-8049
1879-0852
language eng
recordid cdi_proquest_miscellaneous_1492716009
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Conditional survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Male
Medical sciences
Melanoma
Melanoma - mortality
Melanoma - pathology
Melanoma, Cutaneous Malignant
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Netherlands - epidemiology
Pharmacology. Drug treatments
Prognosis
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Survival Analysis
Tumors
Young Adult
title Conditional survival of malignant melanoma in The Netherlands: 1994–2008
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A01%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conditional%20survival%20of%20malignant%20melanoma%20in%20The%20Netherlands:%201994%E2%80%932008&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=van%20der%20Leest,%20Robert%20J.T&rft.date=2014-02-01&rft.volume=50&rft.issue=3&rft.spage=602&rft.epage=610&rft.pages=602-610&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2013.10.019&rft_dat=%3Cproquest_cross%3E1492716009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492716009&rft_id=info:pmid/24262585&rft_els_id=1_s2_0_S095980491300957X&rfr_iscdi=true